New Techniques to evAlUate Response to neOadjuvant Treatments in bReast cAncer (AURORA) (AURORA)
Primary Purpose
Breast Cancer
Status
Unknown status
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Vacuum-assisted breast biopsy
Sponsored by

About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring Breast cancer, Neoadjuvant chemotherapy, Magnetic Resonance Imaging, Contrast mammography, Elastography
Eligibility Criteria
Inclusion Criteria:
- Women with Pathologic diagnosis of breast cancer with indication of neoadjuvant chemotherapy
Exclusion Criteria:
- Breast cancer recurrence
- Other synchronic tumour.
- Inflammatory cancer.
Sites / Locations
- Clínica Universidad de NavarraRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
NAC Patients.
Arm Description
Breast cancer patients after NAC completion, prior to surgery
Outcomes
Primary Outcome Measures
Complete Radiological Response
To evaluate if patients with complete radiological response after NAC, in this setting can be spared breast surgery.
Secondary Outcome Measures
MRI Measurements
To determine if IVIM, KURTOSIS or DTI diffusion sequences in MRI can assess the response to NAC better than conventional sequences and, thus, be able to avoid the use of intravenous contrast in the MRI study in the future.
Elastography
To determine whether the study of breast elastography with shear wave technology, is more sensitive or specific in the detection of residual tumor after NAC in breast cancer.
MRI Comparison
To determining whether contrast enhanced mammography helps us to assess the response to NAC in breast cancer, compared to MRI standard practice.
Full Information
NCT ID
NCT04795349
First Posted
February 25, 2021
Last Updated
March 11, 2021
Sponsor
Clinica Universidad de Navarra, Universidad de Navarra
1. Study Identification
Unique Protocol Identification Number
NCT04795349
Brief Title
New Techniques to evAlUate Response to neOadjuvant Treatments in bReast cAncer (AURORA)
Acronym
AURORA
Official Title
New Techniques to evAlUate Response to neOadjuvant Treatments in bReast cAncer: Can Breast Surgery be Avoided
Study Type
Interventional
2. Study Status
Record Verification Date
February 2021
Overall Recruitment Status
Unknown status
Study Start Date
December 1, 2020 (Actual)
Primary Completion Date
December 2022 (Anticipated)
Study Completion Date
December 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Clinica Universidad de Navarra, Universidad de Navarra
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The role of neoadjuvant chemotherapy (NAC) in breast cancer is well established. Increasing rates of pathologic complete response (pCR) has increased de-escalation of surgical techniques. The objective of the study is to evaluate new radiologic techniques that can accurately detect complete response in order to eliminate breast surgery. . . Currently, there are several imaging techniques for NAC response assessment (magnetic resonance imaging -MRI-, mammography and ultrasound), with good correlation in partial response, but they lack power in predicting complete pathological response. The investigators propose to use IVIM (Intravoxel incoherent motion), Kurtosis (DKI by Diffusion Kurtosis imaging) and diffusion tensor image (DTI) in MRI, contrast enhancement mammography and shear wave elastography for the evaluation of the response to systemic treatment in breast cancer patients. In order to validate the technique, in those patients with a radiological complete response by all the radiological imaging methods, a vacuum-assisted biopsy will be performed before surgery. After that, a comparison will be done between the results of the pre surgical biopsy and the definitive pathology of the specimen. So the investigators can evaluate if patients with complete radiological response after NAC, can be spared breast surgery.
Detailed Description
The role of neoadjuvant chemotherapy (NAC) in breast cancer is well established. In inoperable patients at the time of diagnosis, the goal of NAC is to achieve a pathologic complete response (pCR) which has shown that it improves disease-free survival when compared to those cases with residual tumoral cells. Detection of the presence of residual disease is crucial for surgical planning; the ultimate goal would be to avoid surgery in those patients who achieve a pCR, though nowadays validated techniques with power enough to detect this residual disease are lacking.
Currently, several imaging techniques for NAC response assessment are being used (magnetic resonance imaging -MRI-, mammography and ultrasound), with good correlation in partial response, but they lack power in predicting complete pathological response; among them, nowadays the most accurate is MRI. In recent years, the use of the diffusion-enhanced images have been proposed for the quantitative characterization and for helping to improve the specificity of dynamic contrast study.
The investigators propose to use a bi-exponential model, IVIM (Intravoxel incoherent motion), which differentiates between microperfusion used by microvascular blood flow from the diffusion of water. Kurtosis (DKI by Diffusion Kurtosis imaging) which quantifies the deviation from the Gaussian pattern and diffusion tensor image (DTI) which provides information on the microstructure and pathophysiology tumor, presenting a statistically significant relationship with tumor cellularity. Preliminary studies have reported promising results for the evaluation of the early response to systemic treatment in breast cancer patients. Its utility for NAC response assessment in these patients will be analysed.
Recent studies have evaluated the application of contrast mammography in the assessment of the response to NAC, with MRI-like results. It is a faster and cheaper technique compared to MRI radiological evaluation of the response after NAC through this technique will be assessed and compared its results with the different techniques used in previous studies / in daily practice.
Shear wave elastography is a very useful tool for the quantitative assessment of the tissue hardness that is widely used for differentiating benign lesions from malignant ones. Nowadays some studies are investigating its usefulness in the assessment of the radiological evaluation after NAC, with promising results in terms of early evaluation. In this study, the elastography will be performed on pre surgical evaluation and its correlation with pathological anatomy.
In order to validate the technique, in those patients with a radiological complete response by all the radiological imaging methods, a stereotactic biopsy will be performed before surgery. After that, a comparison will be done between the results of the pre surgical biopsy and the definitive pathology of the specimen. If the false negative rate of the presurgical assessment including the biopsy are below 5%, patients could spare surgery when there is a complete radiological response. Objectives :
To evaluate if patients with complete radiological response after NAC, in this setting can be spared breast surgery. . - To determine if IVIM, KURTOSIS or DTI diffusion sequences in MRI can assess the response to NAC better than conventional sequences and, thus, be able to avoid the use of intravenous contrast in the MRI study in the future. - To determine whether the study of breast elastography with shear wave technology, is more sensitive or specific in the detection of residual tumor after NAC in breast cancer. - To determining whether contrast enhanced mammography helps us to assess the response to NAC in breast cancer, compared to MRI standard practice.
The expected results are:
False negative rate of pre-surgery biopsy <5%. Achieve a sensitivity >80% for the radiological tests in predicting pCR for selected tumoral subtypes (Triple Negative and HER2 enriched tumors).
Noninferiority of contrast mammography compared to breast MRI in determining the response to NAC.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
Breast cancer, Neoadjuvant chemotherapy, Magnetic Resonance Imaging, Contrast mammography, Elastography
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
NAC Patients.
Arm Type
Experimental
Arm Description
Breast cancer patients after NAC completion, prior to surgery
Intervention Type
Procedure
Intervention Name(s)
Vacuum-assisted breast biopsy
Intervention Description
In those patients with a radiological complete response by all the radiological imaging methods, a stereotactic biopsy will be performed before surgery. After that, a comparison will be done between the results of the pre surgical biopsy and the definitive pathology of the specimen.
Primary Outcome Measure Information:
Title
Complete Radiological Response
Description
To evaluate if patients with complete radiological response after NAC, in this setting can be spared breast surgery.
Time Frame
6 months after NAC initiation
Secondary Outcome Measure Information:
Title
MRI Measurements
Description
To determine if IVIM, KURTOSIS or DTI diffusion sequences in MRI can assess the response to NAC better than conventional sequences and, thus, be able to avoid the use of intravenous contrast in the MRI study in the future.
Time Frame
6 months after NAC initiation
Title
Elastography
Description
To determine whether the study of breast elastography with shear wave technology, is more sensitive or specific in the detection of residual tumor after NAC in breast cancer.
Time Frame
6 months after NAC initiation
Title
MRI Comparison
Description
To determining whether contrast enhanced mammography helps us to assess the response to NAC in breast cancer, compared to MRI standard practice.
Time Frame
6 months after NAC initiation
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Women with Pathologic diagnosis of breast cancer with indication of neoadjuvant chemotherapy
Exclusion Criteria:
Breast cancer recurrence
Other synchronic tumour.
Inflammatory cancer.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Carolina Sobrido, MD, PhD
Phone
+34948296666
Ext
6022
Email
csobrido@unav.es
Facility Information:
Facility Name
Clínica Universidad de Navarra
City
Madrid
ZIP/Postal Code
28027
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carolina Sobrido, MD, PhD
Phone
+34948296666
Ext
6022
Email
csobrido@unav.es
First Name & Middle Initial & Last Name & Degree
Carolina Sobrido, MD, PhD
First Name & Middle Initial & Last Name & Degree
Isabel T Rubio, MD, PhD
12. IPD Sharing Statement
Citations:
PubMed Identifier
31912797
Citation
Heil J, Kuerer HM, Pfob A, Rauch G, Sinn HP, Golatta M, Liefers GJ, Vrancken Peeters MJ. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol. 2020 Jan;31(1):61-71. doi: 10.1016/j.annonc.2019.10.012.
Results Reference
background
PubMed Identifier
21947594
Citation
Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol. 2011 Oct;18(11):3160-3. doi: 10.1245/s10434-011-1919-5. Epub 2011 Sep 27.
Results Reference
background
PubMed Identifier
23297042
Citation
Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Irwig L, Mamounas EP, von Minckwitz G, Brennan ME, Ciatto S. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst. 2013 Mar 6;105(5):321-33. doi: 10.1093/jnci/djs528. Epub 2013 Jan 7.
Results Reference
background
PubMed Identifier
25938679
Citation
Sun K, Chen X, Chai W, Fei X, Fu C, Yan X, Zhan Y, Chen K, Shen K, Yan F. Breast Cancer: Diffusion Kurtosis MR Imaging-Diagnostic Accuracy and Correlation with Clinical-Pathologic Factors. Radiology. 2015 Oct;277(1):46-55. doi: 10.1148/radiol.15141625. Epub 2015 May 4.
Results Reference
background
PubMed Identifier
28901594
Citation
Furman-Haran E, Nissan N, Ricart-Selma V, Martinez-Rubio C, Degani H, Camps-Herrero J. Quantitative evaluation of breast cancer response to neoadjuvant chemotherapy by diffusion tensor imaging: Initial results. J Magn Reson Imaging. 2018 Apr;47(4):1080-1090. doi: 10.1002/jmri.25855. Epub 2017 Sep 13.
Results Reference
background
PubMed Identifier
31045431
Citation
Katyan A, Mittal MK, Mani C, Mandal AK. Strain wave elastography in response assessment to neo-adjuvant chemotherapy in patients with locally advanced breast cancer. Br J Radiol. 2019 Jul;92(1099):20180515. doi: 10.1259/bjr.20180515. Epub 2019 May 16.
Results Reference
background
Learn more about this trial
New Techniques to evAlUate Response to neOadjuvant Treatments in bReast cAncer (AURORA)
We'll reach out to this number within 24 hrs